Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Enterprise Value (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Enterprise Value for 6 consecutive years, with -$48.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 39.52% to -$48.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$48.7 million, a 39.52% increase, with the full-year FY2024 number at -$69.8 million, down 21.56% from a year prior.
  • Enterprise Value was -$48.7 million for Q3 2025 at Mereo BioPharma, up from -$56.1 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$48.7 million in Q1 2024 to a low of -$127.1 million in Q4 2021.
  • A 5-year average of -$70.6 million and a median of -$65.3 million in 2022 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: tumbled 310.18% in 2021, then surged 46.36% in 2022.
  • Mereo BioPharma's Enterprise Value stood at -$127.1 million in 2021, then soared by 46.36% to -$68.2 million in 2022, then increased by 15.78% to -$57.4 million in 2023, then fell by 21.56% to -$69.8 million in 2024, then soared by 30.23% to -$48.7 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Enterprise Value are -$48.7 million (Q3 2025), -$56.1 million (Q2 2025), and -$62.5 million (Q1 2025).